Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS) Revenue
Annual & quarterly revenue history · segment & region breakdown
CHRS · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCoherus Oncology, Inc. trailing twelve-month (TTM) revenue is $0.05B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
Compare revenue vs peers
BiotechnologyCompare CHRS revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Coherus Oncology, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Coherus Oncology, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Coherus Oncology, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CHRS revenue · 4 questionsCHRS's trailing twelve-month (TTM) revenue is $0.05B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Coherus Oncology, Inc. SEC filings · GAAP · Coherus Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026